Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FORGOTTEN HISTORY: 2 - The Untold Story

Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial

Exicure, Inc. (NASDAQ:XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.

Benzinga

Tiny Biotech Terns Takes Aim At Novartis' Leukemia Blockbuster

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) on Monday presented updated and expanded data from the ongoing CARDINAL trial of TERN-701 in previously treated chronic myeloid leukemia (CML) patients at the American Society of Hematology Annual Meeting and Exposition.

Benzinga

Why Is Arcellx Stock Surging Today?

Arcellx Inc. (NASDAQ:ACLX) shared new data on Saturday from its pivotal Phase 2 iMMagine-1 study of anitocabtagene autoleucel (anito-cel) for relapsed or refractory multiple myeloma (RRMM).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Pliant Cancer Drug Boosts Responses When Paired With Merck's Blockbuster Keytruda In Tough-To-Treat Tumors

Pliant Therapeutics, Inc. (NASDAQ:PLRX) is capturing attention with promising trial results for its cancer therapy, despite a sharp stock decline.

Benzinga

Janux Therapeutics Stock Hits 52-Week Low After Trial Update

Janux Therapeutics Inc. (NASDAQ:JANX) stock hit a 52-week low on Tuesday after the company released updated interim data for its JANX007 Phase 1 program for metastatic castration-resistant prostate cancer (mCRPC).

Benzinga

AstraZeneca Wins FDA Nod For Imfinzi Combination Regimen In Tough-To-Treat Stomach Cancers

The U.S. Food and Drug Administration (FDA) on Tuesday approved AstraZeneca Plc's (NASDAQ:AZN) Imfinzi (durvalumab) in combination with standard-of-care FLOT chemotherapy (fluorouracil, leucovorin, oxaliplatin, and docetaxel) for resectable, early-stage, and locally advanced gastric and gastroesophageal junction (GEJ) cancers.

Benzinga

Russia's Cancer Drug Approved in Vietnam; Pembroria Finds and Destroys Cancer Cells -- What We Know So Far

Vietnam has approved the Russian cancer drug Pembroria, offering patients a new, cost‑effective treatment option. The move follows deeper health cooperation with Russia and comes as cancer cases in Vietnam nearly double over the past decade.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Oregon family’s life turned upside down after mom and son receive cancer diagnoses on the same day: ‘It was pretty surreal’

The family hopes the little boy will be home in time to celebrate Christmas

The Independent UK

Cancer Detectives: Finding the Cures review – this vaccine documentary is so inspirational it’ll make you weep

The tale of Prof Sarah Blagden’s attempt to find a treatment that stops the disease is the rarest of things – TV that makes you dare to hope

The Guardian - UK

Nuvalent Reports 31% Response Rate In Patients With Advanced Form Of Lung Cancer

Nuvalent, Inc. (NASDAQ:NUVL) on Monday reported topline results from its ALKOVE-1 Phase 1/2 trial.

Benzinga

Zymeworks, Jazz Pharmaceuticals Stocks Climb On Robust Gastroesophageal Trial Outcomes And Upcoming Regulatory Plans

Zymeworks Inc. (NASDAQ:ZYME) stock is surging on Monday, with a session volume of 2.17 million, compared to an average volume of 728.75K, according to Benzinga Pro.

Benzinga

NHS hospital performance in England: Latest numbers and trends

Some 180,329 people had been waiting more than a year to start routine hospital treatment at the end of September.

Evening Standard

EnGene Encouraged By Promising Response Rates In Bladder Cancer Trial

enGene Holdings Inc. (NASDAQ:ENGN) stock is edging higher on Tuesday, with a session volume of 18.62 million compared to an average volume of 266.85 thousand, as per data from Benzinga Pro.

Benzinga

South Carolina pays estate of patient who died following days in agony after surgeons left a blade inside him

Jeffrey Alan Fulcher, a 58-year-old husband and father of three, died after a minimally invasive surgery

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

FDA Clears Johnson & Johnson's Darzalex Faspro, Enabling Early Intervention In Myeloma Progression

The U.S. Food and Drug Administration (FDA) approved on Thursday Johnson Johnson’s (NYSE:JNJ) Darzalex Faspro (daratumumab and hyaluronidase-fihj) for a type of blood cancer.

International Business Times UK

Blood Pressure Medication Recalled Because Of Cancer Risk: What Is Prazosin Hydrochloride

Teva Pharmaceuticals orders a nationwide recall of their Prazosin Hydrochloride capsules.

Benzinga

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Tango Therapeutics Inc. (NASDAQ:TNGX) revealed data from its ongoing Phase 1/2 study of vopimetostat (TNG462) in patients with MTAP-deleted cancers.

The Independent UK

‘Tongue cancer made it hard to speak and eat - but new smart jab treatment changed my life’

Head and neck cancer is the sixth most common cancer worldwide, with around 12,800 new cases each year in the UK alone

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

AstraZeneca/Daiichi Sankyo Partnered Breast Cancer Drug Shows Survival Benefit Over Chemotherapy

AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo on Monday released high-level results from the TROPION-Breast02 Phase 3 trial.

The Independent UK

Sunbeds should be banned in the UK to cut skin cancer rates, experts say

Exposure to ultraviolet radiation from sunbeds was confirmed to be carcinogenic to humans in 2009 by the International Agency for Research on Cancer.

Metal Hammer

Sick Of It All singer Lou Koller says his oesophageal cancer has returned

The hardcore vocalist was first diagnosed with the disease in summer 2024 and said he was cancer-free in May

Benzinga

Sanofi Expands Insulin Savings Program To Cover All US Patients

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation.

The Guardian - UK

Three in four English hospitals failing to hit two cancer targets in league tables

Exclusive: Cancer experts declare ‘national emergency’ as hospitals miss targets on diagnosis and starting treatment

The Independent UK

Warning after cancer patients died following delays in getting life-saving emergency drugs

More than a dozen cancer patients have either died or become seriously ill after not getting rasburicase

Benzinga

EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers

Hoth Therapeutics Inc. (NASDAQ:HOTH) on Tuesday announced combined findings from multiple preclinical programs evaluating its precision antisense candidate HT-KIT.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

The Institute of Cancer Research

The Royal Marsden NHS Foundation Trust

23 stories

Melanoma Focus

22 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.